Amgen Inc. (AMGN)

US — Healthcare Sector
Peers: MRK  ABBV  GILD  JNJ  BMY  PFE  LLY  BIIB 

Automate Your Wheel Strategy on AMGN

With Tiblio's Option Bot, you can configure your own wheel strategy including AMGN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol AMGN
  • Rev/Share 63.4312
  • Book/Share 11.5372
  • PB 26.3115
  • Debt/Equity 9.2446
  • CurrentRatio 1.1704
  • ROIC 0.0953

 

  • MktCap 163226033360.0
  • FreeCF/Share 20.2881
  • PFCF 14.9543
  • PE 27.5266
  • Debt/Assets 0.6421
  • DivYield 0.0305
  • ROE 0.9294

 

  • Rating B+
  • Score 3
  • Recommendation Neutral
  • P/E Score 2
  • DCF Score 5
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Resumed AMGN Guggenheim -- Neutral -- $288 May 20, 2025
Resumed AMGN Cantor Fitzgerald -- Neutral -- $305 April 22, 2025
Resumed AMGN BofA Securities -- Underperform -- $256 Dec. 10, 2024
Initiation AMGN Bernstein -- Outperform -- $380 Oct. 17, 2024
Downgrade AMGN Truist Buy Hold $320 $333 Oct. 14, 2024
Initiation AMGN Cantor Fitzgerald -- Overweight -- $405 Sept. 27, 2024

News

Amgen Gears Up to Report Q2 Earnings: Will the Beat Streak Continue?
AMGN
Published: July 30, 2025 by: Zacks Investment Research
Sentiment: Neutral

AMGN eyes another earnings beat as strong drug volumes offset pricing pressure and biosimilar headwinds.

Read More
image for news Amgen Gears Up to Report Q2 Earnings: Will the Beat Streak Continue?
Amgen (AMGN) Just Flashed Golden Cross Signal: Do You Buy?
AMGN
Published: July 29, 2025 by: Zacks Investment Research
Sentiment: Positive

Amgen Inc. (AMGN) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, AMGN's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.

Read More
image for news Amgen (AMGN) Just Flashed Golden Cross Signal: Do You Buy?
5 Dogs of the Dow Are Crushing the S&P 500 and Nasdaq in 2025
AMGN, CVX, JNJ, KO, VZ
Published: July 28, 2025 by: 24/7 Wall Street
Sentiment: Neutral

The Dogs of the Dow is a well-known strategy first published in 1991 by Michael O'Higgins.

Read More
image for news 5 Dogs of the Dow Are Crushing the S&P 500 and Nasdaq in 2025
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
AMGN
Published: July 28, 2025 by: Zacks Investment Research
Sentiment: Positive

Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Read More
image for news Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
Amgen vs. Novo Nordisk: Which Pharma Giant Is the Better Buy?
AMGN, NVO
Published: July 23, 2025 by: Zacks Investment Research
Sentiment: Positive

AMGN's deep pipeline and rare disease expansion may outweigh NVO's GLP-1 dominance and leadership shakeup.

Read More
image for news Amgen vs. Novo Nordisk: Which Pharma Giant Is the Better Buy?
NodThera Announces Appointment of Dr. Jyothis George as Chief Medical Officer
AMGN
Published: July 21, 2025 by: GlobeNewsWire
Sentiment: Neutral

NodThera Announces Appointment of Dr. Jyothis George as Chief Medical Officer Former Amgen, Novo Nordisk and Boehringer Ingelheim senior leader joins NodThera Leadership Team Will spearhead clinical advancement of the company's innovative NLRP3 inflammasome inhibitor portfolio Brings deep clinical leadership in obesity and cardiometabolic diseases, with a proven track record guiding programs from early-stage development through Phase 3 and regulatory approval Philadelphia, PA, July 21, 2025 - NodThera, a leading clinical-stage biotech delivering a paradigm shift in the treatment of chronic inflammatory diseases through selective modulation of the NLRP3 inflammasome, today announces the appointment of Dr. Jyothis George, M.D., Ph.D., …

Read More
image for news NodThera Announces Appointment of Dr. Jyothis George as Chief Medical Officer
Undercovered Dozen: Christian Dior, Coca-Cola, Trinity Capital, Amgen And More
AMGN, CHDRF, CHDRY, KO, TRIN
Published: July 18, 2025 by: Seeking Alpha
Sentiment: Neutral

This week's Undercovered Dozen spotlights 12 lesser-known stocks with compelling investment theses, spanning micro-nuclear, luxury, biotech, and high-yield BDCs. Highlighted opportunities include NANO Nuclear Energy's niche potential, Christian Dior SE's LVMH exposure, and Harrow's explosive growth in ophthalmic pharmaceuticals. Coca-Cola and Ares Capital are flagged as overvalued or increasingly risky, with warnings of unsustainable growth and looming corrections for investors.

Read More
image for news Undercovered Dozen: Christian Dior, Coca-Cola, Trinity Capital, Amgen And More
Can Amgen (AMGN) Keep the Earnings Surprise Streak Alive?
AMGN
Published: July 17, 2025 by: Zacks Investment Research
Sentiment: Positive

Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Read More
image for news Can Amgen (AMGN) Keep the Earnings Surprise Streak Alive?
What Makes Amgen (AMGN) a New Buy Stock
AMGN
Published: July 15, 2025 by: Zacks Investment Research
Sentiment: Positive

Amgen (AMGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Read More
image for news What Makes Amgen (AMGN) a New Buy Stock
Are Medical Stocks Lagging Amgen (AMGN) This Year?
AMGN
Published: July 15, 2025 by: Zacks Investment Research
Sentiment: Negative

Here is how Amgen (AMGN) and Aldeyra Therapeutics, Inc. (ALDX) have performed compared to their sector so far this year.

Read More
image for news Are Medical Stocks Lagging Amgen (AMGN) This Year?
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
AMGN
Published: July 15, 2025 by: Zacks Investment Research
Sentiment: Positive

Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Read More
image for news Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
Amgen (AMGN) is a Top-Ranked Growth Stock: Should You Buy?
AMGN
Published: July 14, 2025 by: Zacks Investment Research
Sentiment: Positive

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Read More
image for news Amgen (AMGN) is a Top-Ranked Growth Stock: Should You Buy?
Amgen (AMGN) Outperforms Broader Market: What You Need to Know
AMGN
Published: July 02, 2025 by: Zacks Investment Research
Sentiment: Positive

The latest trading day saw Amgen (AMGN) settling at $296.85, representing a +2.18% change from its previous close.

Read More
image for news Amgen (AMGN) Outperforms Broader Market: What You Need to Know
Final Trades: Amgen, Caterpillar, Honeywell and Freeport-McMoran
AMGN, CAT, FCX, HON
Published: July 02, 2025 by: CNBC Television
Sentiment: Neutral

The Investment Committee give you their top stocks to watch for the second half.

Read More
image for news Final Trades: Amgen, Caterpillar, Honeywell and Freeport-McMoran
Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know
AMGN
Published: July 01, 2025 by: Zacks Investment Research
Sentiment: Positive

Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Read More
image for news Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know
Amgen's gastric cancer drug meets late-stage trial goal
AMGN
Published: June 30, 2025 by: Reuters
Sentiment: Positive

Amgen said on Monday its experimental cancer therapy, when combined with chemotherapy, met the main goal in a late-stage trial.

Read More
image for news Amgen's gastric cancer drug meets late-stage trial goal
Amgen Looks to Take Share of Booming Obesity Space: Will It Succeed?
AMGN
Published: June 27, 2025 by: Zacks Investment Research
Sentiment: Positive

Amgen aims to challenge obesity drug leaders with MariTide, a potential monthly treatment now in late-stage trials.

Read More
image for news Amgen Looks to Take Share of Booming Obesity Space: Will It Succeed?
Here's Why Amgen (AMGN) is a Strong Growth Stock
AMGN
Published: June 27, 2025 by: Zacks Investment Research
Sentiment: Positive

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Read More
image for news Here's Why Amgen (AMGN) is a Strong Growth Stock
Here's Why Amgen (AMGN) is a Strong Value Stock
AMGN
Published: June 25, 2025 by: Zacks Investment Research
Sentiment: Positive

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Read More
image for news Here's Why Amgen (AMGN) is a Strong Value Stock
What's Happening With Amgen Stock?
AMGN
Published: June 24, 2025 by: Forbes
Sentiment: Negative

Amgen stock (NASDAQ:AMGN) fell 6% on Monday, June 23, 2025, after mid-stage clinical trial results for its long-acting experimental obesity drug, MariTide, revealed a need for a low starting dose to mitigate side effects like vomiting. Amgen plans to proceed with Phase 3 trials, initiating patients on a lower dosage that will gradually increase with an eight-week dose escalation period.

Read More
image for news What's Happening With Amgen Stock?
Low start dose of Amgen experimental weight-loss drug limits side effects
AMGN
Published: June 23, 2025 by: Reuters
Sentiment: Positive

People started on a low dose of Amgen's long-acting experimental obesity drug MariTide lost as much weight as those given high doses but with milder side effects, according to full results of a mid-stage trial presented at a medical meeting on Monday.

Read More
image for news Low start dose of Amgen experimental weight-loss drug limits side effects
RESULTS FROM AMGEN'S PHASE 2 OBESITY STUDY OF MONTHLY MARITIDE PRESENTED AT THE AMERICAN DIABETES ASSOCIATION 85TH SCIENTIFIC SESSIONS
AMGN
Published: June 23, 2025 by: PRNewsWire
Sentiment: Neutral

MariTide, the First Monthly or Less Frequently Dosed Obesity Treatment, Demonstrated Up to ~20% Average Weight Loss Without a Weight Loss Plateau, and Delivered Significant Cardiometabolic Improvements at 52 Weeks In People Living With Obesity With Type 2 Diabetes, MariTide Demonstrated Up to ~17% Average Weight Loss and Robust HbA1c Improvements Dose Escalation With Lower Starting Doses Substantially Improved Gastrointestinal Tolerability, Without Compromising Efficacy The MARITIME Phase 3 Chronic Weight Management Studies are Actively Enrolling, and Phase 3 Studies in People Living With Atherosclerotic Cardiovascular Disease, Heart Failure and Obstructive Sleep Apnea Will be Initiated in 2025 THOUSAND OAKS, Calif. …

Read More
image for news RESULTS FROM AMGEN'S PHASE 2 OBESITY STUDY OF MONTHLY MARITIDE PRESENTED AT THE AMERICAN DIABETES ASSOCIATION 85TH SCIENTIFIC SESSIONS
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
AMGN
Published: June 20, 2025 by: Zacks Investment Research
Sentiment: Positive

Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.

Read More
image for news Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
Here's Why Amgen (AMGN) is a Strong Momentum Stock
AMGN
Published: June 11, 2025 by: Zacks Investment Research
Sentiment: Positive

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Read More
image for news Here's Why Amgen (AMGN) is a Strong Momentum Stock
Why Amgen (AMGN) is a Top Growth Stock for the Long-Term
AMGN
Published: June 10, 2025 by: Zacks Investment Research
Sentiment: Positive

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Read More
image for news Why Amgen (AMGN) is a Top Growth Stock for the Long-Term
Why Amgen (AMGN) is a Top Value Stock for the Long-Term
AMGN
Published: June 09, 2025 by: Zacks Investment Research
Sentiment: Positive

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Read More
image for news Why Amgen (AMGN) is a Top Value Stock for the Long-Term
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
AMGN
Published: June 09, 2025 by: Zacks Investment Research
Sentiment: Positive

Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.

Read More
image for news Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
Amgen's Strategic Path - Navigating Patent Expiries With Promising New Therapies
AMGN
Published: June 06, 2025 by: Seeking Alpha
Sentiment: Neutral

Amgen faces major revenue risk from upcoming patent cliffs but has promising pipeline drugs like MariTide and olpasiran to offset losses. Recent financials show solid revenue growth and improved margins, though net selling prices and legacy drugs like Enbrel remain under pressure. Valuation analysis reveals AMGN is priced for no growth, offering 27% upside if the company achieves even modest revenue increases.

Read More
image for news Amgen's Strategic Path - Navigating Patent Expiries With Promising New Therapies
Profit From the Silver Tsunami: Must-Watch Senior Care & Aging Stocks
ABBV, AMGN, BSX, DXCM
Published: June 04, 2025 by: Zacks Investment Research
Sentiment: Positive

BSX, ABBV, AMGN and DXCM are tapping into the aging boom with cutting-edge tech, chronic care drugs and senior-focused innovations.

Read More
image for news Profit From the Silver Tsunami: Must-Watch Senior Care & Aging Stocks
Amgen's Imdelltra Cuts Lung Cancer Death Risk by 40% in Phase III
AMGN
Published: June 03, 2025 by: Zacks Investment Research
Sentiment: Negative

AMGN's Imdelltra slashes lung cancer death risk by 40% in Phase III, extending survival by over five months compared to chemotherapy.

Read More
image for news Amgen's Imdelltra Cuts Lung Cancer Death Risk by 40% in Phase III

About Amgen Inc. (AMGN)

  • IPO Date 1983-06-17
  • Website https://www.amgen.com
  • Industry Drug Manufacturers - General
  • CEO Robert A. Bradway
  • Employees 28000

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.